SARS-COV-2 VACCINE SUPPLY AGREEMENT

Procurement of Novavax's vaccine candidate NVX-CoV2373, as intended for the prophylaxis and vaccination against SARS-CoV-2 in humans.

Note:

This notice corrects and supersedes a previous notice (see links section).

It does not represent a new arrangement or contract with the supplier.

Additional information: Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vaccine vendors and (iii) impact fair competition between vaccine vendors .

Contract end date is being withheld on grounds that release of the information would be contrary to public interest under Regulation 50(6)(a). The contract end date is variable based on production and delivery of the requirement. There are significant challenges to overcome and the end date may not be a true reflection, setting unrealistic expectation for the public and in the market. This information is also being withheld on due to commercial sensitivity under Regulation 50(6)(b) and (c) as there is significant competition to develop and bring to the market a successful vaccine. Provision of the contract term may provide valuable information to competitors that may impact negotiations or future competition in the market. Sub-contractor details are being withheld on grounds that release of the information would be contrary to public interest under Regulation 50(6)(a). This information is very sensitive given potential for targeting and disruption of the activities at the facilities which would be contrary to public interest as these activities are critical to success and delivery of the requirement.